In most solid tumors, high numbers of regulatory T (Treg) cells are associated with poorer outcomes because they dampen the ...
CNW/ - Takeda Canada Inc. ("Takeda") is pleased to announce that FRUZAQLATM (fruquintinib capsules) will now be reimbursed by ...
Takeda Canada Inc. ("Takeda") is pleased to announce that FRUZAQLATM (fruquintinib capsules) will now be reimbursed by BC ...
Oncolytics Biotech® Inc. (Nasdaq: ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing ...
A new study from Memorial Sloan Kettering Cancer Center finds that in colorectal cancer, not all regulatory T cells are ...
The results of the study could improve immunotherapy treatment for patients with colorectal and other barrier-tissue cancers.
The U.S. Food and Drug Administration (FDA) has granted fast track designation to muzastotug when used in combination with Keytruda (pembrolizumab) to treat adult patients with microsatellite stable ...
In patients with stage II-III rectal cancer, non-operative management after a clinical complete response to neoadjuvant ...
Daily scans taken during prostate cancer radiotherapy could be repurposed to guide changes to treatment, reducing the risk of ...
Older Americans with metastatic breast, colorectal, lung, or prostate cancer are spending an increasing amount of time in the ...
The FDA's fast track designation acknowledges the combination's promising early efficacy and safety profile in treating MSS mCRC. Early data from a phase 1b/2 study showed deep, durable responses with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback